Differentiated thyroid carcinoma:: The new UICC 6th edition TNM classification system in a retrospective analysis of 169 patients

被引:40
作者
Döbert, N
Menzel, C
Oeschger, S
Grünwald, F
机构
[1] Goethe Univ Frankfurt, Dept Nucl Med, D-6000 Frankfurt, Germany
[2] Goethe Univ Frankfurt, Senckenberg Dept Pathol, D-6000 Frankfurt, Germany
关键词
D O I
10.1089/105072504322783867
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: To compare the new, 6th edition, UICC TNM staging system with the former edition, we updated TNM staging in patients with differentiated thyroid carcinoma. Methods: The new and old TNM classification systems for differentiated thyroid carcinoma were applied in a retrospective analysis of 169 patients who underwent therapy with radioiodine (I-131) from 1975 through 2002 at the Department of Nuclear Medicine, Frankfurt. Results: According to the new staging system, 83 patients (49%) were classified as T1 compared to 54 patients (32%) based on the former edition; 32 patients (19%) as T2 compared to 61 (36%) patients formerly. In 44 patients with minimal extrathyroid extension, formerly classified T4, the new TNM staging changed to T3, and no patient was classified T4. The one year relapse-free survival fraction under the former edition staging was 100% for T1 and 92.2% for T2, compared to 96.8% for new edition T1 and 93.3% for T2. Conclusion: The new TNM classification causes a significant change in staging. New T1 classified tumors had a slightly worse relapse-free survival fraction compared with the old T1 carcinomas. For patients treated at our department, the altered criteria for classifying extrathyroid extensions have had only a minor impact on disease management.
引用
收藏
页码:65 / 70
页数:6
相关论文
共 19 条
[1]  
[Anonymous], 2002, TNM CLASSIFICATION M
[2]  
Baudin E, 1998, CANCER, V83, P553, DOI 10.1002/(SICI)1097-0142(19980801)83:3<553::AID-CNCR25>3.0.CO
[3]  
2-U
[4]   Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients [J].
Baudin, E ;
Do Cao, C ;
Cailleux, AF ;
Leboulleux, S ;
Travagli, JP ;
Schlumberger, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (03) :1107-1111
[5]   THE CLINICIAN AND THE THYROID [J].
BIERSACK, HJ ;
HOTZE, A .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1991, 18 (09) :761-778
[6]   Pupillary microcarcinoma of the thyroid gland [J].
Bramley, MD ;
Harrison, BJ .
BRITISH JOURNAL OF SURGERY, 1996, 83 (12) :1674-1683
[7]  
Brierley JD, 1997, CANCER, V79, P2414
[8]  
Denoix PF, 1944, B I NAT HYG PARIS, V1, P1
[9]  
Dietlein M, 1999, NUKLEARMED, V38, P221
[10]  
Hermanek P, 1996, CANCER, V77, P815, DOI 10.1002/(SICI)1097-0142(19960301)77:5<815::AID-CNCR1>3.0.CO